Literature DB >> 19487797

Review of the newest HPLC methods with mass spectrometry detection for determination of immunosuppressive drugs in clinical practice.

Magdalena Korecka1, Leslie M Shaw.   

Abstract

High performance liquid chromatography coupled with electrospray mass spectrometry is widely used for quantitative determination of immunosuppressive drugs (sirolimus, tacrolimus, everolimus, CsA and MPA) in biological fluids. The growth in volume for testing these drugs and economic constraints in clinical laboratories has led to heightened demand for high throughput methods. Fast-flow on-line extraction with switching valve technique and implementation of automation accelerates sample preparation. For on-line purification the combination of fast flow of washing solution and narrow-bore extraction column provides a clean sample in a very short time without compromising precision and accuracy. The unique feature of multireactant monitoring tandem mass spectrometry reduces significantly the need for chromatographic separation, as long as matrix effects are not detected, and permits simultaneous measurement of several drugs in one run when they are present in the same specimen. Additionally, the same method together with the identical sample preparation and HPLC-MS conditions and setting can be used for measurement of all five immunosuppressants, four of them in blood, MPA in plasma. Thanks to the high sensitivity of LC-MS only a small volume of biological sample is required for analysis. However for MPA quantitation, mass interference attributable to in-source fragmentation of its glucuronide metabolite can be a problem if the latter is not chromatographically separated from the parent drug before introduction of the sample into the ion source. Thus, chromatographic separation is extremely important for MPA analysis. In conclusion, important features of LC-MS methodology for immunosuppressive drugs include: shortened analysis time, increased throughput, selectivity and lower cost of analysis.<br /> <br />

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19487797

Source DB:  PubMed          Journal:  Ann Transplant        ISSN: 1425-9524            Impact factor:   1.530


  5 in total

1.  Silica coated paper substrate for paper-spray analysis of therapeutic drugs in dried blood spots.

Authors:  Zhiping Zhang; Wei Xu; Nicholas E Manicke; R Graham Cooks; Zheng Ouyang
Journal:  Anal Chem       Date:  2011-12-23       Impact factor: 6.986

2.  Long-term cross-validation of everolimus therapeutic drug monitoring assays: the Zortracker study.

Authors:  Björn Schniedewind; Stefanie Niederlechner; Jeffrey L Galinkin; Kamisha L Johnson-Davis; Uwe Christians; Eric J Meyer
Journal:  Ther Drug Monit       Date:  2015-06       Impact factor: 3.681

3.  Rapid estimation of whole blood everolimus concentrations using architect sirolimus immunoassay and mathematical equations: comparison with everolimus values determined by liquid chromatography/mass spectrometry.

Authors:  Amitava Dasgupta; Vanessa Moreno; Shawn Balark; Andre Smith; Marilyn Sonilal; Neelam Tejpal; Charles T Van Buren
Journal:  J Clin Lab Anal       Date:  2011       Impact factor: 2.352

4.  Performance of the Dimension TAC assay and comparison of multiple platforms for the measurement of tacrolimus.

Authors:  Eun-Jung Cho; Dae-Hyun Ko; Woochang Lee; Sail Chun; Hae-Kyung Lee; Won-Ki Min
Journal:  J Clin Lab Anal       Date:  2017-11-17       Impact factor: 2.352

Review 5.  Alternative matrices for therapeutic drug monitoring of immunosuppressive agents using LC-MS/MS.

Authors:  Mwlod Ghareeb; Fatemeh Akhlaghi
Journal:  Bioanalysis       Date:  2015       Impact factor: 2.681

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.